GeneTx Biotherapeutics is a company that was set up as a subsidiary of the Foundation for Angelman Syndrome Therapeutics for the development and commercialization of an investigational antisense drug, GTX-102, for treating Angelman syndrome.
The company builds on several years of research, community engagement, and scientific discoveries. The sole mission of GeneTx is to see an effective therapeutic for Angelman syndrome commercialized.
GeneTx Biotherapeutics (GeneTx) is committed to developing therapy for Angelman syndrome. Its investigational product, GTX-102, is currently in a Phase 1/2 clinical trial in order to understand the potential risks and benefits of this experimental drug.